Sei Investments Co. Cuts Stock Position in argenx SE (NASDAQ:ARGX)

Sei Investments Co. reduced its position in argenx SE (NASDAQ:ARGX - Free Report) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 366,620 shares of the company's stock after selling 14,075 shares during the period. Sei Investments Co. owned 0.60% of argenx worth $225,475,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares during the last quarter. Janus Henderson Group PLC lifted its position in argenx by 0.4% during the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company's stock valued at $1,343,797,000 after purchasing an additional 10,975 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of argenx by 13.0% in the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company's stock worth $261,470,000 after buying an additional 55,617 shares in the last quarter. Alkeon Capital Management LLC increased its holdings in shares of argenx by 15.0% in the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company's stock worth $187,018,000 after buying an additional 45,000 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of argenx by 27.0% during the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock valued at $185,821,000 after buying an additional 64,183 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Remove Ads

argenx Stock Performance

argenx stock traded down $4.68 during midday trading on Tuesday, hitting $603.27. 61,472 shares of the company's stock were exchanged, compared to its average volume of 285,225. argenx SE has a 12 month low of $352.77 and a 12 month high of $678.21. The company has a market cap of $36.66 billion, a PE ratio of -685.20 and a beta of 0.59. The firm has a 50-day moving average of $633.44 and a two-hundred day moving average of $600.67.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on ARGX. Citigroup reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. JMP Securities raised their price target on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Oppenheimer boosted their price objective on shares of argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, argenx presently has an average rating of "Moderate Buy" and a consensus target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.